Vitamin D may not help your heart

While previous research has suggested a link between low levels of vitamin D in the blood and an increased risk of cardiovascular disease, a new Michigan State University study has found that taking vitamin D supplements did not reduce that risk. The large-scale study, published in the Journal of the American Medical Association Cardiology, found that vitamin D supplements did not decrease the incidence of heart attacks, strokes or other major adverse cardiovascular events.

"We thought it would show some benefit," said Mahmoud Barbarawi, a clinical instructor in the MSU College of Human Medicine and chief resident physician at Hurley Medical Center in Flint, Michigan. "It didn't show even a small benefit. This was surprising."

His finding was consistent for both men and women and for patients of different ages.

Many earlier studies have found an association of low levels of vitamin D in the blood and an increased risk of cardiovascular disease, suggesting that vitamin D supplements might reduce that risk.

Barbarawi led a team of researchers and reviewed data from 21 clinical trials, including more than 83,000 patients. Half the patients were administered vitamin D supplements, and half were given placebos. The meta-analysis of data showed no difference in the incidences of cardiovascular events or all causes of death between the two groups.

Vitamin D sometimes is known as the sunshine vitamin, because human skin makes vitamin D when exposed to the sun. Thus, those living farthest from the equator tend to have lower levels of vitamin D in their blood.

While some studies have found a link between low levels of the vitamin and an increased risk of adverse cardiovascular events, Barbarawi's study suggests that other factors, such as outdoor physical activity and nutritional status, might explain the association.

Barbarawi also noted that even though his findings showed no effect on heart health, some patients, such as those being treated for osteoporosis, still might benefit from the supplements.

As a result, he suggests that doctors and patients think twice about taking the vitamin to minimize the chances of a heart attack or other cardiovascular issues.

"We don't recommend taking vitamin D to reduce this risk," Barbarawi said.

Mahmoud Barbarawi, Babikir Kheiri, Yazan Zayed, Owais Barbarawi, Harsukh Dhillon, Bakr Swaid, Anitha Yelangi, Saira Sundus, Ghassan Bachuwa, Mohammad Luay Alkotob, JoAnn E Manson.
Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis.
JAMA Cardiol. Published online June 19, 2019. doi: 10.1001/jamacardio.2019.1870.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...